Reducing off target viral delivery in ovarian cancer gene therapy using a protease-activated AAV2 vector platform.
Tong JG, Evans AC, Ho ML, Guenther CM, Brun MJ, Judd J, Wu E, Suh J
J Control Release. 2019 Jun 25. pii: S0168-3659(19)30367-0. doi: 10.1016/j.jconrel.2019.06.034.
(Link opens in a new window)
PubMed
(Link opens in a new window)
Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 129024 | pProvector_AAV2_586_PLGLAR | Recombinant AAV2 rep/cap plasmid modified to include an 18 amino acid peptide at cap position 586. |